Radioligand Therapy Market
Radioligand Therapy Market Size, Share, Competitive Landscape and Trend Analysis Report by Product, Target, Indications and End Users: Global Opportunity and Industry Forecast (2025-2032)
Report ID:
1172
Industry:
Healthcare
Published on:
March 2026
Global Radioligand Therapy Market had a value of USD 2.43 Billion in 2025 and expected it to hit USD 5.2 Billion by 2032, with a CAGR of 13.5 % during the forecast period.
Radioligand Therapy Trends and Analytical Insights -
North America Radioligand Therapy Market was the largest revenue generating region market in year 2025, with market share accounted for 42 %.
In 2025, Product Type segment, Lutetium-177 dominated the Radioligand Therapy, accounted for 52 % market shares.
Leading Key players for Radioligand Therapy Market in 2025 was Novartis AG, Bayer AG, Curium Pharma, Telix Pharmaceuticals and ITM Isotope Technologies Munich SE.
Radioligand Therapy Market Size & Forecast
Market Size 2025: USD 2.43 Billion
Projected Market Size 2032: USD 5.2 Billion
CAGR (2025-2032): 13.5%
North America: Dominating market in 2025
Radioligand Therapy Market Overview
Radioligand Therapy Market is the global market that deals with targeted cancer therapy, Radioligand therapy is a type of cancer treatment that uses radiation to kill the cancer cells. Radioligand therapy is a targeted form of cancer therapy that delivers radiation directly to cancer cells with less harm to healthy tissues. In 2025, over 250,000 patients globally received targeted radionuclide therapies, which is a 14% rise from 2022. The rising number of cases of prostate cancer and neuroendocrine tumors had increased the relevance of radioligand therapies. Clinical trials had demonstrated response rates of over 60% in patients with advanced prostate cancer who received lutetium-177-based therapies.
The Radioligand Therapy Market is mainly driven by the convergence of nuclear medicine, oncology, and precision diagnostics. In 2025 More than 180 clinical trials involving radioligand therapy were ongoing globally, up from 110 trials in 2020. Hospitals and cancer centers have stepped up spending on nuclear imaging equipment by almost 18% over the last three to four years. The need for theranostics, or the integration of diagnosis and treatment, had helped to ensure clinical adoption. The production of medical isotopes such as lutetium-177 and actinium-225 has risen by about 22% from 2021 to 2025 to keep up with the growing number of therapy procedures. This steady clinical adoption makes Radioligand Therapy Market a strategic area of focus in next-generation cancer therapy platforms.
Radioligand Therapy Market Dynamic’s
The global increase in cancer incidence has led to a rising demand for radioligand therapy. In 2025, more than 20 million people would have developed cancer, with prostate cancer accounting for around 1.4 million of these cases. Improved progression-free survival rates of approximately 8 months have been seen when compared with chemotherapy in targeted uses, and hospitals have increased their PET imaging capabilities by about 16%, allowing better identification of patients. There have been collective investments by pharmaceutical companies in nuclear medicine R&D of over $3 billion from 2021 to 2025. Healthcare providers continue to focus on precision oncology and minimizing systemic toxicity. Reimbursement models for these structured therapies in 12 or more developed countries are being improved upon from 2023 to 2025, enhancing their availability.
Within the Radioligand Therapy market there were multiple logistics and infrastructure challenges. Specifically, actinium-225 production was below 100 curies per year as of 2025 and therefore limiting the large-scale applicability of therapies in clinical settings. Short half-life isotopes necessitated use of fast distribution times and effective cold chain management systems. In addition, healthcare organizations made capital investments of more than USD 5 million to establish nuclear medicine departments. There remained a shortage of qualified radio pharmacists and trained radiation safety personnel in newly created healthcare organizations.
The Radioligand Therapy Market is expected to provide substantial growth opportunities through the diversification of pipeline therapies and the development of combination therapies. By 2026, over 50 radioligand therapy candidates are anticipated to enter Phase II and Phase III clinical trials. Research institutions are expected to form collaborations with pharmaceutical companies to develop alpha-emitting therapies, which are anticipated to show improved tumor cell killing efficiency by up to 30% in preclinical and early clinical assessments. The investment in isotope production facilities is expected to grow by a further 30% from 2025 to 2027, which will help stabilize supplies and end treatment delays. Governments in the Asia-Pacific region are expected to commit over USD 1.5 billion to modernization of healthcare initiatives over the next three years. This will help enhance nuclear medicine facilities and will also promote the adoption of innovative radiopharmaceutical therapies, which will help the Radioligand Therapy Market grow in the long term.
From 2022 to 2025, regulatory bodies were approving several lutetium-177-based therapies for prostate-specific membrane antigen. The production capacity for medical isotopes was growing due to newly installed reactors and cyclotron centers in Europe and North America. Collaborations between cancer therapy companies and nuclear technology companies were rising by almost 19% in 2023 compared to the previous year. AI-based imaging solutions were enhancing the accuracy of tumor detection by almost 15%. In 2025, at least five large pharmaceutical acquisitions were targeting nuclear medicine, which was enhancing competitive positioning. Uninterrupted investments in research were upgrading the supply chain and were strengthening the competitiveness of the Radioligand Therapy Market.
Radioligand Therapy Market Segment Analysis
The Radioligand Therapy Market is segmented into By Product, Target, Indications and End Users
By Product,
The Radioligand Therapy Market is segmented into Fluorine-18, Gallium-68, Lutetium-177, and Others. In 2025, the Lutetium-177 segment was leading the Radioligand Therapy Market in terms of the usage of total products, accounting for around 52% of the market. Lutetium-177 was commonly used in therapeutic settings, especially for treating prostate cancer and neuroendocrine tumors. Clinical trials were showing response rates of over 60% in advanced cases of prostate cancer treated with Lutetium-177-based radioligand therapy. The production levels of Lutetium-177 had risen by almost 22% between 2021 and 2025 to cater to the rising demand for treatment. It’s ideal half-life of about 6 to 7 days was facilitating smooth logistics and hospital-based administration.
By Target,
On the basis of target, the Radioligand Therapy Market is segmented into Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), and Others. In 2025, the Prostate-specific Membrane Antigen (PSMA) segment led the Radioligand Therapy Market, accounting for close to 48% of the total target-based therapy. PSMA-targeted therapy was extensively used for metastatic castration-resistant prostate cancer, which accounted for over 1.4 million new cases of prostate cancer every year globally. Clinical trials were showing a 40% improvement in progression-free survival in patients with PSMA-positive growth. The use of PSMA PET imaging rose by around 15% between 2022 and 2025, which improved the accuracy of patient identification.
Radioligand Therapy Market Region Analysis
In 2025, the North America region was leading the Radioligand Therapy Market with a share of 42% of the global market. The United States was having more than 2,000 PET imaging centers that were supporting strong diagnostic capacity. The regulatory bodies were granting early approvals for targeted radionuclide therapies. Healthcare bodies were investing close to USD 800 million between 2021 and 2025 in upgrades of nuclear medicine technology. Reimbursement programs were supporting the accessibility of structured therapies. Research institutions and pharmaceutical companies were collaborating actively, which was accelerating the clinical trials and commercialization processes in oncology facilities.
Radioligand Therapy Market Competitive Analysis
The Radioligand Therapy Market was being highly competitive with the involvement of key players like Novartis AG, Bayer AG, Eli Lilly and Company, Curium Pharma, and ITM Isotope Technologies Munich SE. These players were emphasizing on diversification of their pipelines, partnerships for isotope production, and acquisitions. During 2022-2025, more than 15 collaboration agreements were being inked to enhance the manufacturing networks. The investment in alpha-emitter research was rising by almost 20% in 2023. The players were optimizing their supply chains and were extending their clinical trial programs to enhance their position in the Radioligand Therapy Market.
Radioligand Therapy Market Scope:
Radioligand Therapy Market Key Players –
Bayer AG
Curium Pharma
ITM Isotope Technologies Munich SE
Eli Lilly and Company
Progenics Pharmaceuticals
Ariceum Therapeutics
Convergent Therapeutics Inc.
Actinium Pharmaceuticals Inc.
Radiopharm Theranostics
Nordic Nanovector
Y-mAbs Therapeutics
Ratio Therapeutics
Frequently Ask Questions –
1) Which cancer type was leading Radioligand Therapy Market adoption?
Ans - Prostate cancer was leading Radioligand Therapy Market adoption with more than 50% therapy utilization in 2025.
2) What was driving Radioligand Therapy Market?
Ans - Rising cancer incidence, increasing precision medicine adoption, and growing isotope production were driving Radioligand Therapy Market.
3) Which isotope type was dominating Radioligand Therapy Market?
Ans - Beta-emitting isotopes were dominating Radioligand Therapy Market with nearly 68% usage share in 2025.
4) Which region was leading Radioligand Therapy Market?
Ans - North America was leading Radioligand Therapy Market with advanced nuclear medicine infrastructure and early regulatory approvals.
5) Which isotope was widely used in the Radioligand Therapy Market?
Ans - Lutetium-177 was widely used in the Radioligand Therapy Market for targeted treatment of prostate and neuroendocrine tumors.